 <p><b>Lower Costs, More Cures Act of 2021</b></p> <p>This bill establishes and modifies several programs and requirements to address prescription drug prices. </p> <p>The bill modifies provisions under Medicare and Medicaid relating to prescription drug coverage and price transparency. Among other changes, the bill</p> <ul> <li>requires the Centers for Medicare &amp; Medicaid Services to publish certain information, as reported by pharmacy benefit managers (PBMs), relating to generic dispensing rates, drug discounts and rebates, and payments between PBMs, health plans, and pharmacies;</li> <li> caps annual out-of-pocket spending under the Medicare prescription drug benefit;</li> <li>allows prescription drug plan sponsors under the Medicare prescription drug benefit to offer additional plans in a region; </li> <li> requires pass-through pricing models, and prohibits spread-pricing, for payment arrangements with PBMs under Medicaid; and </li> <li>allows states to include in the Medicaid Drug Rebate Program covered outpatient drugs that are provided as part of physician or outpatient hospital services.</li> </ul> <p>The bill also generally modifies other provisions relating to the regulation and costs of generic and brand-name drugs. Among other changes, the bill</p> <ul> <li>prohibits the manufacturer of a brand-name, generic, or biosimilar drug from entering into certain agreements to resolve or settle a patent infringement claim in connection with the sale of a drug or biological product;</li> <li>permanently allows high deductible health plans to waive deductibles for insulin and associated products; and</li> <li>establishes the position of Chief Pharmaceutical Negotiator in the Office of the U.S. Trade Representative.</li> </ul>